MedTrace Logo

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

NCT00343109 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-02-12

No results posted yet for this study

Summary

This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells

Conditions

Interventions

BIOLOGICAL

HER-2/neu intracellular domain protein

Given ID

PROCEDURE

leukapheresis

Optional correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

sargramostim

Given ID

OTHER

immunologic technique

Correlative studies

BIOLOGICAL

synthetic tumor-associated peptide vaccine therapy

Given ID

Sponsors & Collaborators

Principal Investigators

  • Mary Disis · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00343109 on ClinicalTrials.gov